| Accession |
PRJCA022297 |
| Title |
RNA-seq molecular subtypes and gene expression signatures in the phase 3 IMpower151 study of 1L bevacizumab + pemetrexed/paclitaxel ± atezolizumab in metastatic NSCLC |
| Relevance |
Medical |
| Data types |
Transcriptome or Gene expression
Variation
|
| Organisms |
Homo sapiens
|
| Description |
A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF BEVACIZUMAB, CARBOPLATIN, AND PACLITAXEL OR PEMETREXED WITH OR WITHOUT ATEZOLIZUMAB IN CHEMOTHERAPY-NAIVE PATIENTS WITH STAGE IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER |
| Sample scope |
Multiisolate |
| Release date |
2024-04-05 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Roche/Genentech
|
|
NA
|
|
|
|
| Submitter |
ling
zhang (shfkgcp@163.com)
|
| Organization |
shanghai pulmonary hospital |
| Submission date |
2023-12-22 |
